Literature DB >> 30209196

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.

Jason Weatherald1,2,3,4,5,6, Athénaïs Boucly1,2,3,6, David Launay7,8,9,10, Vincent Cottin11,12, Grégoire Prévot13, Delphine Bourlier14, Claire Dauphin15, Ari Chaouat16,17,18, Laurent Savale1,2,3, Xavier Jaïs1,2,3, Mitja Jevnikar1,2,3, Julie Traclet11,12, Pascal De Groote18, Gérald Simonneau1,2,3, Eric Hachulla7,8,9,10, Luc Mouthon19,20, David Montani1,2,3, Marc Humbert1,2,3,6, Olivier Sitbon21,2,3,6.   

Abstract

The prognostic importance of follow-up haemodynamics and the validity of multidimensional risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH).We assessed incident SSc-PAH patients to determine the association between clinical and haemodynamic variables at baseline and first follow-up right heart catheterisation (RHC) with transplant-free survival. RHC variables included cardiac index, stroke volume index (SVI), pulmonary arterial compliance and pulmonary vascular resistance. Risk assessment was performed according to the number of low-risk criteria: functional class I or II, 6-min walking distance (6MWD) >440 m, right atrial pressure <8 mmHg and cardiac index ≥2.5 L·min-1·m-2Transplant-free survival from diagnosis (n=513) was 87%, 55% and 35% at 1, 3 and 5 years, respectively. At baseline, 6MWD was the only independent predictor. A follow-up RHC was available for 353 patients (median interval 4.6 months, interquartile range 3.9-6.4 months). The 6MWD, functional class, cardiac index, SVI, pulmonary arterial compliance and pulmonary vascular resistance were independently associated with transplant-free survival at follow-up, with SVI performing better than other haemodynamic variables. 1-year outcomes were better with increasing number of low-risk criteria at baseline (area under the curve (AUC) 0.63, 95% CI 0.56-0.69) and at first follow-up (AUC 0.71, 95% CI 0.64-0.78).Follow-up haemodynamics and multidimensional risk assessment had greater prognostic significance than at baseline in SSc-PAH.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 30209196     DOI: 10.1183/13993003.00678-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  16 in total

Review 1.  Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Authors:  Shu-Hao Wu; Yih-Jer Wu
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

2.  Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension.

Authors:  Katharine R Clapham; Kristin B Highland; Youlan Rao; Wassim H Fares
Journal:  Front Cardiovasc Med       Date:  2020-04-30

3.  Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.

Authors:  Masataka Kuwana; Christiana Blair; Tomohiko Takahashi; Jonathan Langley; John G Coghlan
Journal:  Ann Rheum Dis       Date:  2020-03-11       Impact factor: 19.103

Review 4.  The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.

Authors:  Michael H Lee; Todd M Bull
Journal:  F1000Res       Date:  2019-12-19

Review 5.  Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact.

Authors:  Mario Naranjo; Paul M Hassoun
Journal:  Diagnostics (Basel)       Date:  2021-05-20

6.  Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification.

Authors:  Yue Shi; Yanling Meng; Xingbei Dong; Yang Liu; Yongtai Liu; Jinzhi Lai; Zhuang Tian; Jiuliang Zhao; Jinmin Peng; Qian Wang; Mengtao Li; Xiaofeng Zeng
Journal:  Pulm Circ       Date:  2021-07-11       Impact factor: 3.017

7.  Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Authors:  Vasiliki Kalliopi Bournia; Iraklis Tsangaris; Loukianos Rallidis; Dimitrios Konstantonis; Frantzeska Frantzeskaki; Anastasia Anthi; Stylianos E Orfanos; Eftychia Demerouti; Panagiotis Karyofillis; Vassilis Voudris; Katerina Laskari; Stylianos Panopoulos; Panayiotis G Vlachoyiannopoulos; Petros P Sfikakis
Journal:  Diagnostics (Basel)       Date:  2020-01-19

8.  CD248 as a novel therapeutic target in pulmonary arterial hypertension.

Authors:  Tao Xu; Lei Shao; Aimei Wang; Rui Liang; Yuhan Lin; Guan Wang; Yan Zhao; Jing Hu; Shuangyue Liu
Journal:  Clin Transl Med       Date:  2020-09

9.  Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?

Authors:  Jason Weatherald; Athénaïs Boucly; Laurent Savale; Xavier Jaïs; David Montani; Marc Humbert; Olivier Sitbon
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

10.  Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment.

Authors:  Clara Hjalmarsson; Barbro Kjellström; Kjell Jansson; Magnus Nisell; David Kylhammar; Mohammad Kavianipour; Göran Rådegran; Stefan Söderberg; Gerhard Wikström; Dirk M Wuttge; Roger Hesselstrand
Journal:  ERJ Open Res       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.